Download PDF
CC BY-NC-ND 4.0 · Journal of Coloproctology 2023; 43(03): e171-e178
DOI: 10.1055/s-0043-1772784
Original Article

Identification of Potential Urinary Protein Biomarkers in Colorectal Cancer: A Pilot Study Using a Proteomic Approach

Bruno Augusto Alves Martins 
1   Department of Colorectal Surgery, School of Medicine, University of Brasilia, Brasilia, Brazil
,
Raphaela Menezes de Oliveira 
2   Cell Biology Department, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil
,
Mickaella Michelson Martins 
2   Cell Biology Department, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil
,
Paulo Gonçalves de Oliveira 
1   Department of Colorectal Surgery, School of Medicine, University of Brasilia, Brasilia, Brazil
,
Aline Maria Araújo Martins 
3   Medical Science Graduate Program, School of Medicine, University of Brasilia, Brasilia, Brazil
› Author Affiliations Funding Statement This research did not receive any specific grant from funding agencies in the public, commercial, or non-profit sectors.
› Further Information
Also available at
   Permissions and Reprints


Abstract

Colorectal cancer (CRC) is among the most diagnosed malignancies worldwide, and it is also the second leading cause of cancer-related deaths. Despite recent progress in screening programs, noninvasive accurate biomarkers are still needed in the CRC field. In this study, we evaluated and compared the urinary proteomic profiles of patients with colorectal adenocarcinoma and patients without cancer, aiming to identify potential biomarker proteins. Urine samples were collected from 9 patients with CRC and 9 patients with normal colonoscopy results. Mass spectrometry (label-free LC‒MS/MS) was used to characterize the proteomic profile of the groups. Ten proteins that were differentially regulated were identified between patients in the experimental group and in the control group, with statistical significance with a p value ≤ 0.05. The only protein that presented upregulation in the CRC group was beta-2-microglobulin (B2M). Subsequent studies are needed to evaluate patients through different analysis approaches to independently verify and validate these biomarker candidates in a larger cohort sample.

Keywords

Colorectal cancer - biomarkers - translational research - proteomics - mass spectrometry


Publication History

Received: 13 March 2023

Accepted: 21 June 2023

Article published online:
21 September 2023

© 2023. Sociedade Brasileira de Coloproctologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71 (03) 209-249
    Search in Google Scholar
  • 2 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71 (01) 7-33
    CrossrefPubMedSearch in Google Scholar
  • 3 Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. Am J Gastroenterol 2021; 116 (03) 458-479
    CrossrefPubMedSearch in Google Scholar
  • 4 Davidson KW, Barry MJ, Mangione CM. et al; US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 325 (19) 1965-1977
    CrossrefPubMedSearch in Google Scholar
  • 5 Bailey JR, Aggarwal A, Imperiale TF. Colorectal Cancer Screening: Stool DNA and Other Noninvasive Modalities. Gut Liver 2016; 10 (02) 204-211
    CrossrefPubMedSearch in Google Scholar
  • 6 Bond JH. Fecal occult blood test screening for colorectal cancer. Gastrointest Endosc Clin N Am 2002; 12 (01) 11-21
    CrossrefPubMedSearch in Google Scholar
  • 7 Gonzalez-Pons M, Cruz-Correa M. Colorectal Cancer Biomarkers: Where Are We Now?. BioMed Res Int 2015; 2015: 149014
    CrossrefPubMedSearch in Google Scholar
  • 8 Alves Martins BA, de Bulhões GF, Cavalcanti IN, Martins MM, de Oliveira PG, Martins AMA. Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research. Front Oncol 2019; 9: 1284
    CrossrefPubMedSearch in Google Scholar
  • 9 Feng B, Yue F, Zheng M. Chapter 2 Urinary Markers in Colorectal Cancer. In: Advances in Clinical Chemistry. Vol 47. Elsevier; 2009: 45-57
    CrossrefSearch in Google Scholar
  • 10 Coronado BNL, da Cunha FBS, de Oliveira RM. et al. Novel Possible Protein Targets in Neovascular Age-Related Macular Degeneration: A Pilot Study Experiment. Front Med (Lausanne) 2022; 8: 692272
    CrossrefPubMedSearch in Google Scholar
  • 11 Ciocan-Cartita CA, Jurj A, Buse M. et al. The Relevance of Mass Spectrometry Analysis for Personalized Medicine through Its Successful Application in Cancer “Omics”. Int J Mol Sci 2019; 20 (10) 2576
    CrossrefPubMedSearch in Google Scholar
  • 12 Alnabulsi A, Murray GI. Proteomics for early detection of colorectal cancer: recent updates. Expert Rev Proteomics 2018; 15 (01) 55-63
    CrossrefPubMedSearch in Google Scholar
  • 13 Iwasaki H, Shimura T, Kataoka H. Current status of urinary diagnostic biomarkers for colorectal cancer. Clin Chim Acta 2019; 498: 76-83
    CrossrefPubMedSearch in Google Scholar
  • 14 Casado-Vela J, Gómez del Pulgar T, Cebrián A, Álvarez-Ayerza N, Lacal JC. Human urine proteomics: building a list of human urine cancer biomarkers. Expert Rev Proteomics 2011; 8 (03) 347-360
    CrossrefPubMedSearch in Google Scholar
  • 15 Sun Y, Guo Z, Liu X. et al. Noninvasive urinary protein signatures associated with colorectal cancer diagnosis and metastasis. Nat Commun 2022; 13 (01) 2757
    CrossrefPubMedSearch in Google Scholar
  • 16 Li L, Dong M, Wang XG. The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. Chin Med J (Engl) 2016; 129 (04) 448-455
    CrossrefPubMedSearch in Google Scholar
  • 17 Prizment AE, Linabery AM, Lutsey PL. et al. Circulating Beta-2 Microglobulin and Risk of Cancer: The Atherosclerosis Risk in Communities Study (ARIC). Cancer Epidemiol Biomarkers Prev 2016; 25 (04) 657-664
    CrossrefPubMedSearch in Google Scholar
  • 18 Kloor M, Michel S, Buckowitz B. et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer 2007; 121 (02) 454-458
    CrossrefPubMedSearch in Google Scholar
  • 19 Tikidzhieva A, Benner A, Michel S. et al. Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. Br J Cancer 2012; 106 (06) 1239-1245
    CrossrefPubMedSearch in Google Scholar
  • 20 Nomura T, Huang WC, Zhau HE, Josson S, Mimata H, Chung LW. β2-Microglobulin-mediated signaling as a target for cancer therapy. Anticancer Agents Med Chem 2014; 14 (03) 343-352
    CrossrefPubMedSearch in Google Scholar
  • 21 Botelho TEF, Pereira AK, Teixeira PG, Lage EM, Osanan GC, Silva AC. Uromodulin: a new biomarker of fetal renal function?. J Bras Nefrol 2016; 38 (04) 427-434
    CrossrefPubMedSearch in Google Scholar
  • 22 Trevisani F, Larcher A, Cinque A. et al. The Association of Uromodulin Genotype with Renal Cancer Aggressiveness. Eur Urol Focus 2019; 5 (02) 262-265
    CrossrefPubMedSearch in Google Scholar
  • 23 Sandim V, Pereira Dde A, Kalume DE. et al. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma. Urol Oncol 2016; 34 (01) 5.e11-5.e25
    CrossrefPubMedSearch in Google Scholar
  • 24 Xin R, Tang XM, Jiang YJ. et al. Construction of a Novel MYC-Associated ceRNA Regulatory Network to Identify Prognostic Biomarkers in Colon Adenocarcinoma. J Oncol 2022; 2022: 3216285
    CrossrefPubMedSearch in Google Scholar
  • 25 Yao L, Lao W, Zhang Y. et al. Identification of EFEMP2 as a serum biomarker for the early detection of colorectal cancer with lectin affinity capture assisted secretome analysis of cultured fresh tissues. J Proteome Res 2012; 11 (06) 3281-3294
    CrossrefPubMedSearch in Google Scholar
  • 26 Zhai X, Xue Q, Liu Q, Guo Y, Chen Z. Colon cancer recurrence–associated genes revealed by WGCNA co–expression network analysis. Mol Med Rep 2017; 16 (05) 6499-6505
    CrossrefPubMedSearch in Google Scholar
  • 27 Simsek O, Kocael A, Kemik A. et al. Decreased preoperative serum fibulin-3 levels in colon cancer patients. Eur Rev Med Pharmacol Sci 2015; 19 (21) 4076-4080
    PubMedSearch in Google Scholar
  • 28 Tong JD, Jiao NL, Wang YX, Zhang YW, Han F. Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma 2011; 58 (05) 441-448
    CrossrefPubMedSearch in Google Scholar
  • 29 Bröker MEE, Lalmahomed ZS, Roest HP. et al. Collagen peptides in urine: a new promising biomarker for the detection of colorectal liver metastases. PLoS One 2013; 8 (08) e70918
    CrossrefPubMedSearch in Google Scholar
  • 30 Kehlet SN, Sanz-Pamplona R, Brix S, Leeming DJ, Karsdal MA, Moreno V. Excessive collagen turnover products are released during colorectal cancer progression and elevated in serum from metastatic colorectal cancer patients. Sci Rep 2016; 6 (01) 30599
    CrossrefPubMedSearch in Google Scholar
  • 31 Zou X, Feng B, Dong T. et al. Up-regulation of type I collagen during tumorigenesis of colorectal cancer revealed by quantitative proteomic analysis. J Proteomics 2013; 94: 473-485
    CrossrefPubMedSearch in Google Scholar
  • 32 Yu Y, Liu D, Liu Z. et al. The inhibitory effects of COL1A2 on colorectal cancer cell proliferation, migration, and invasion. J Cancer 2018; 9 (16) 2953-2962
    CrossrefPubMedSearch in Google Scholar
  • 33 van Huizen NA, Coebergh van den Braak RRJ, Doukas M, Dekker LJM, IJzermans JNM, Luider TM. Up-regulation of collagen proteins in colorectal liver metastasis compared with normal liver tissue. J Biol Chem 2019; 294 (01) 281-289
    CrossrefPubMedSearch in Google Scholar
  • 34 Rassart E, Bedirian A, Do Carmo S. et al. Apolipoprotein D. Biochim Biophys Acta 2000; 1482 (1-2): 185-198
    CrossrefPubMedSearch in Google Scholar
  • 35 Ren L, Yi J, Li W. et al. Apolipoproteins and cancer. Cancer Med 2019; 8 (16) 7032-7043
    CrossrefPubMedSearch in Google Scholar